IonOpticks 纳流色谱柱与温控系统

This separation took place on a commercially available reverse-phase C18 column with an integrated CaptiveSpray Emitter (25 cm × 75 μm ID, 1.6 μm, AuroraSeries with CSI, IonOpticks).

Peptides were loaded onto a C18 trap column (75 μm × 2 cm, 3 μm particles, 100 Å, Thermo) and separated on an analytical column (75 μm × 15 cm, 1.7 μm particles, 100 Å, IonOpticks) using a gradient of mobile phase A (0.1% formic acid) and B (0.1% formic acid in acetonitrile) at a flow rate of 300 nL/min.

IonOpticks, Fitzroy, VIC, Australia).

After the trypsin digestion as described above, 0.5 µL of each tryptic peptide mixture sample was injected, and separated using an ACQUITY nanoLC system (Waters, Milford, USA) equipped with an Aurora Elite C18 column (1.7 µm, 25 cm×75 um, IonOpticks, Collingwood, Australia).

The DIA liquid chromatography elution conditions were as follows: flow rate of 400 nL/min, C18 analytical column (15 cm × 75 μm ID, 1.6 μm C18, IonOpticks), buffer A consisted of 0.1% FA in water, and buffer B consisted of 0.1% FA/80% ACN/20% water.

Briefly, peptides were loaded onto a reversed-phase C18 column (Ionopticks, 1.6 μm, 75 μm×250 mm) and separated using a 44-minutes linear gradient from mobile phases A (water with 2% ACN and 0.1% formic acid) to B (water with 80% ACN and 0.1% formic acid).

IonOpticks, Melbourne, Australia) at a flow rate of 300 nL/min using a 90 min linear gradient of 2–35% mobile phase B (0.1% FA in acetonitrile) in mobile phase A (0.1% FA in water).

The chromatographic separation employed a DIA-enabled LC system configured with: 400 nL/min flow rate through a 15 cm × 75 μm ID C18 analytical column (IonOpticks, 1.6 μm beads), using mobile phase A (0.1% formic acid in water) and phase B (0.1% formic acid in acetonitrile).

IonOpticks, Victoria, Australia).

Peptide extracts were loaded on the trapping column, Waters ACQUITY UPLC M-Class Symmetry C18 Trap column, 100 A, 5 µm, 180 µm × 20 mm and eluted with the analytical column, IonOpticks Aurora Elite CSI 15 × 75 C18 UHPLC column.

Frontiers in Psychology 1664-1078 Frontiers Media SA PMC12855123 PMC12855123.1 12855123 12855123 41625461 10.3389/fpsyg.2025.1716551 1 Original Research Museotherapy as a method: an investigation into the emotional experiences of Chinese youth visitors Wang Siyi 1 * Conceptualization Funding acquisition Methodology Project administration Resources Supervision Validation Writing

Materials and methods Data were acquired from the TCGA-BRCA, AURORA US Network, SCAN-B, and GEO databases.

Cyclin-dependent kinases (CDKs), aurora kinases, BUB1B A, CCNB1, BUB1, CCNB2, and CDCA8 are serine/threonine kinases that are considered promising targets for cancer therapy.

Footnotes Edited by: Animesh Kumar Paul , University of Alberta, Canada Reviewed by: Suzel Chavaglia , Universidade Federal do Triângulo Mineiro, Brazil Aurora Torres Soto , Autonomous University of Aguascalientes, Mexico Khalid Been Md.

This domain-focused strategy aligns conceptually with recent developments in foundation models such as Aurora ( 16 ), which uses large-scale self-supervised pretraining to deliver multidomain Earth system forecasts.

Data acquisition and analysis: Stained cells were acquired on a Cytek Aurora spectral flow cytometer (Cytek Biosciences) configured with five lasers (355, 405, 488, 561, and 640 nm).

Cell viability and purity were assessed by flow cytometry (Cytek Aurora 4L, Cytek Biosciences) following staining with LIVE/DEAD Fixable Violet Dead Cell Stain (Invitrogen) and BV711-conjugated anti-human CD20 antibody (clone 2H7, BD Biosciences), with purity and cell viability around 95%.

For instance, the Aurora kinase family (AURKA, AURKB) and its downstream effectors (e.g., PLK1, CDC20) are often overexpressed in a range of malignancies, are linked to a bad prognosis, and play important roles in the control of spindle checkpoint (SAC).

Flow cytometry analysis was conducted using the Cytek Aurora system (Cytek Biosciences), and the data were processed with FlowJo software.

These systems provide a holistic fingerprint of a sample’s headspace but are notoriously plagued by poor reproducibility ( Liu et al., 2023a ), drift over time ( Chou et al., 2023 ), and acute sensitivity to ambient interferents such as humidity and temperature variations ( Aurora, 2022 ).

Cinobufagin exhibits excellent anti-tumor effects in liver cancer cells by inhibiting the Aurora Kinase A (AURKA)-mTOR-eucalyptic translation initiation factor 4E (eIF4E) axis ( Jin et al., 2020 ).

and (C) Enrichment score (ES) curves for pathways including “Metabolism of RNA”, “Processing of Capped Intron Containing Pre - mRNA”, “mRNA Splicing”, and “Aurora B Pathway” during GSEA.

pmc eLife Elife 1894 elife eLife eLife 2050-084X eLife Sciences Publications, Ltd PMC12959880 PMC12959880.1 12959880 12959880 41778583 10.7554/eLife.108802 108802 1 version of record Research Article Chromosomes and Gene Expression Acetylation of H3K115 is associated with fragile nucleosomes at CpG island promoters and active regulatory sites Kumar Yatendra https://orcid.org/00

leadership or fiduciary role (paid or unpaid) for: AstraZeneca PLC, HutchMed (China) Ltd, Aurora Pharma Ltd, Epoch Biosciences Inc., Insighta;

Aurora, CO: University of Colorado;

For phellodendrine, 11 common targets were identified (including aurora kinase A, fatty acid synthase, and prostaglandin-endoperoxide synthase 1/2), with the highest binding affinity predicted for the Prostaglandin-endoperoxide synthase 2 protein (docking score: −7.183).

For instance, based on the aforementioned observation of high TP53 mutation frequency, enrichment of cell cycle-related pathways, and downregulation of apoptosis pathways, the ECMSig-low group exhibited an increased dependency on proliferative and anti-apoptotic signaling, consistent with their sensitivity to PLK1 inhibition (BI-2536), 26 Aurora kinases inhibition (tozasertib),

Aurora RN, Punjabi NM.

In addition, the CHK2–BRCA1 signaling axis helps maintain mitotic integrity by suppressing Aurora-A kinase activity and ensuring proper spindle assembly [ 46 ].

Aurora A.L.

Aurora RN Kristo DA Bista SR Rowley JA Zak R Casey KR .

The method used Aurora Elite XT 15×75 C18 UHPLC column with an EASY-Spray ion source, improving protein identification from approximately 2,000 to 5,000-6,500 proteins per single cell.

The methodology involved sophisticated peptide separation using an Aurora Ultimate CSI 25×75 C18 UHPLC column , operated at 50°C with a 50-minute gradient.

Approximately 200 ng of the sample was loaded onto a AUR3-15075C18 analytical column (IonOpticks, Fitzroy, Australia) and separated using a 60-min gradient at a column temperature of 50 °C.

LC-MS/MS analysis Peptides were separated on a nanoElute UHPLC (Bruker Daltonics, Germany) using an Ionopticks Aurora C18 column (250 ​mm ​× ​75 ​μm, 1.6 ​μm) (Ionopticks, Australia).

Samples were reconstituted in 0.1% formic acid (FA), and 200 ng peptide was separated using an AUR3-15075C18 column (15 cm length, 75 μm i.d, 1.7 μm particle size, and 120 Å pore size, IonOpticks, Collingwood, VIC, Australia), with a 60 min gradient starting at 4% buffer B (80% acetonitrile (can) containing 0.1% FA), followed by a stepwise increase to 28% over 25 min, 44% over

IonOpticks, Victoria, Australia) at 50 °C (column oven;

IonOpticks).

A volume of 1 μL (approximately 200 ng of the protein digest) was injected into the UHPLC system and separated on an IonOpticks 25 cm Aurora Ultimate Series Emitter column with Captive Spray Insert (250 mm × 75 μm internal diameter, 120 Å pore size, 1.7 μm particle size C18) at a flow rate of 0.3 μL/min.

Briefly, the C18-reversed phase column (75 μm × 25 cm, Ionopticks, Little Rock, AR, USA) was equilibrated with solvent A (2% ACN with 0.1% formic acid) and solvent B (80% ACN with 0.1% formic acid).

In brief, liquid chromatography-mass spectrometry (LC-MS) was employed to separate concentrated peptides using a 25 cm C18 analytical column (25 cm × 75μm ID, 1.6μm C18, IonOpticks) at a flow rate of 300nL/min.

Peptides were separated in 90 min at a flow rate of 300 nL min −1 on a 25 cm × 75 µm column (1.6 µm C18, ionopticks).

IonOpticks).

IonOpticks, Fitzroy, Australia) at 60 °C with a solvent gradient using 0.1 % FA in water (Solvent A) and 99.9 % ACN/0.1 % FA in water (Solvent B), at a flow rate of 400 nL min −1 .

The peptides were separated on a 75 μm × 250 mm IonOpticks Aurora 3 C18 column (Ion Opticks).

Peptides were first trapped using a trapping column (Acclaim PepMap 100 C18 HPLC, particle size of 75 μm, bed length of 2 cm) and then separated using analytical column AUR3-25075C18, 25CM Aurora Series Emitter Column (25 cm by 75 μm, 1.7 μm, C18) (IonOpticks).

Anlotinib, a novel multitarget TKI which inhibits VEGF/VEGFR, PDGFRa/b, c-Kit, Ret, Aurora-B, c-FMS and DDR1 ( 27 ), showed antitumor activity in advanced liposarcoma in a multicenter phase II trial.

GYG2 and its co-expressed protein are involved in regulating integrin 1 pathway and aurora B pathway in glioma.

These bridges can become trapped by the cleavage furrow in late telophase, activating the Aurora B-dependent abscission checkpoint, which delays cytokinesis and allows a final attempt to process the trapped chromatin 6 – 10 .

The factors and molecular pathways implicated in the initiation and progression of BOTs are intricate and diverse, with ongoing discovery and exploration of diagnostic markers such as AGR2 ( Armes et al., 2013 ), Rb/p105 ( Masciullo et al., 2020 ), Aurora ( Alkhateeb et al., 2021 ), among others.

24 424 17.67 14 Cincinnati Children's Hospital Medical Center Aurora, Paul 22 674 30.64 49 Great Ormond Street Hospital for Children Faro, Albert 19 401 21.11 25 Washington University Visner, Gary A.

Binding was analyzed using a BD Accuri C6 (BD Biosciences) or Cytek Aurora (Cytek Biosciences) flow cytometer after secondary incubation with a fluorescein isothiocyanate (FITC)-labeled goat anti-mouse antibody, unless stated otherwise.

Antibody anti-Aurora B mouse (Becton Dickinson;

pmc eLife Elife 1894 elife eLife eLife 2050-084X eLife Sciences Publications, Ltd PMC12416886 PMC12416886.1 12416886 12416886 40920087 10.7554/eLife.104138 104138 1 version of record Research Article Immunology and Inflammation Aurora kinase A promotes trained immunity via regulation of endogenous S-adenosylmethionine metabolism Li Mengyun https://orcid.org/0000-0002-1889-6306

5 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$P{LQY}=\frac{\int {I}_{{PL}}d\lambda }{\int {I}_{{BG}}-{I}_{{sample}}d\lambda }$$\end{document} P LQY = ∫ I PL d λ ∫ I BG − I sample d λ 6 \document

Peptides were separated by nanoflow UPLC (Aurora C18 column) and analyzed in data-independent acquisition (DIA) mode on a Bruker timsTOF Pro instrument.

Scholars have discovered more and more related proteins (e.g., aurora-related kinases) [ 171 ] and pathways (Plk1) [ 172 ] that have an effect on EBs, which might broaden the exploration of the entire MT dynamics network.

Correlation analyses revealed that the level of eccDNA was strongly correlated with the expression of proliferation-associated genes, e.g., MKI67 (gene encoding Ki67), AURKA (gene encoding aurora kinase A), and CDK1 (gene encoding CDK1) ( Fig.

Alisertib is a selective inhibitor of Aurora kinase (AURK) A, a key regulator of mitotic progression and spindle formation [ 24 , 59 ].

pmc eLife Elife 1894 elife eLife eLife 2050-084X eLife Sciences Publications, Ltd PMC12263152 PMC12263152.1 12263152 12263152 40662934 10.7554/eLife.95324 95324 1 version of record Research Article Genetics and Genomics Medicine EPHA4 signaling dysregulation links abnormal locomotion and the development of idiopathic scoliosis Wang Lianlei 1 2 3 4 † Yang Xinyu https://orcid.org